Pfizer Inc said on Monday its cancer drug, Bosulif, was found superior to Novartis AG's Gleevec in a late-stage study on untreated patients with a form of blood and bone marrow cancer characterized by abnormal white blood cells production.
If investors are looking for a stable dividend stock with upside, Pfizer Inc. (NYSE:PFE) could be one that fits the bill. The stock currently provides a dividend yield of 3.79% for the Healthcare company.
Pfizer Inc. (PFE) managed to rebound with the stock climbing 0.54% or $0.17 to close the day at $31.63 on light trading volume of 18.98M shares, compared to its three month average trading volume of 24.54M.
Pfizer Inc. (NYSE:PFE) stock is one of the biggest gainers from Donald Trump's surprise victory in the U.S. presidential race on speculation that his term will be less hostile to pharmaceutical and biotech companies.
Pfizer Inc. (NYSE:PFE) and Eli Lilly and Co (NYSE:LLY) are yet again the subject of immense criticism as their practice of increasing the prices of key drugs in the impotence drug market in tandem continues to leave patients with no other options.